PTC wins conditional EU Translarna approval
This article was originally published in Scrip
Executive Summary
PTC Therapeutics has been granted conditional approval from the European Commission for its Duchenne muscular dystrophy (DMD) drug Translarna (ataluren), which has yet to produce Phase III data.